Nantahala Capital Management

InspireMD is a medical device company based in Tel Aviv, Israel, dedicated to developing and commercializing its proprietary MicroNet stent platform technology for treating vascular and coronary diseases across Europe, Latin America, the Middle East, and Asia. The company offers the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection systems, which cater to patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft interventions. Additionally, InspireMD is working on the NGuard, a neurovascular flow diverter aimed at diverting blood flow from cerebral aneurysms. The company markets its products through local distributors, striving to address critical clinical challenges in stenting, such as embolic showers, restenosis, and late stent thrombosis, while aiming to establish its technology as the industry standard.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.

Keystone Dental was founded in March 2006, and aspires to build a market leading, global brand recognized within the dental community for its integrity, trust and commitment to improving the standard of care for patients and their quality of life. Since then, they have rapidly grown into a diversely skilled, fast-moving team of professionals committed to providing excellent customer service and producing high-quality products and services.

DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.